ClinicalTrials.gg
RecruitingNCT06383143ProDigALItyUpdated Apr 16, 2026

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

An observational study in AL Amyloidosis, Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 4 sites in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
760
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia — 6 open to participants now, 6 under way, none of them phase 3. Immunoglobulin Light-chain Amyloidosis · Fondazione IRCCS Policlinico San Matteo di Pavia.

Started
2023
the only one that year
Observational
7 of 13
6 open now
Registered
10th of 13
by date

Among the 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia, this one is the only one that started in 2023, is one of 7 observational ones, and was the 10th registered.

Immunoglobulin Light-chain Amyloidosis

239 studies on the registry are indexed under Immunoglobulin Light-chain Amyloidosis; 63 are open to participants now.

Browse Immunoglobulin Light-chain Amyloidosis studies →

Open to participants now

6 of the 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Immunoglobulin Light-chain Amyloidosis by Fondazione IRCCS Policlinico San Matteo di Pavia, or all of them as a file.
02

Study summary

The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to:

  1. Implement a biomarker-based screening strategy to promote early diagnosis of AL amyloidosis among at-risk patients, including patients with monoclonal gammopathy of undetermined significance, MGUS, and altered free light chain ratio (aFLCR), and patients with smoldering multiple myeloma (SMM)
  2. Expedite and facilitate patients' referral and their enrollment in ongoing pre-clinical/clinical studies, also to reflect a broader spectrum of the real-world population of patients with AL amyloidosis in Italy;
  3. Investigate the clinical utility of novel diagnostic technologies, including light chain sequencing and N-glycosylation analysis
Read the detailed description

AL amyloidosis (AL) is a rare, severe protein conformational disease caused by misfolding and extracellular deposition of patients-specific monoclonal immunoglobulin light chains in form of amyloid fibrils. This process can affect virtually any body site and result in potentially fatal organ dysfunction.

In a significant proportion of cases, AL is diagnosed late, when advanced, often irreversible organ involvement limits therapeutic options and greatly limits survival. Thus, efforts at promoting early diagnosis are urgently needed.

The presence of a monoclonal protein (M protein) or an abnormally increased concentration of serum free LCs (FLCs) invariably precedes clinically overt AL amyloidosis by several years. Moreover, about 95% of patients with AL have an altered FLC ratio (FLCR) at diagnosis. Yet, AL is often diagnosed late also in patients with known monoclonal gammopathy under hematological follow-up. Screening of at-risk patients with biomarkers of early amyloid organ involvement has been advocated, but not largely implemented.

Diagnosis and management of AL patients require access to sophisticated technologies and expertise available at large tertiary Amyloid Centers. Yet, new models of patients' care are required to intercept those patients who cannot travel to distant, tertiary centers, in order to provide state-of-the-art care to all and to be able to analyze and describe the natural history of the disease in a contemporary, real-world setting.

New molecular features associated with the propensity of light chains to form amyloid are emerging, but their potential clinical utility is unknown. Building on >30 years-experience of the Italian Referral Center for Systemic Amyloidoses and leveraging on an already existing disease registry and a one-of-a-kind biorepository of clinically annotated biological samples, the study plans to extend and corroborate the activity of the Italian Amyloidosis Network, through the involvement of large Hematology Departments strategically distributed across the Country and the establishment of a structured program of patients' referral and sample/data transfer.

The study will be conducted as follows:

Part A: an active biomarker-based surveillance of pre-symptomatic signs of amyloid organ involvement in at-risk subjects (patients with MGUS and aFLCR and patients with SMM) will be implemented in the participating Italian Hematologic Departments. This will enable the verification of the feasibility of such biomarker-based screening, allow the description of baseline characteristics of at-risk patients, and promote early diagnosis of AL amyloidosis.

Part B: newly diagnosed AL amyloidosis patients (either from Part A or from patients with clinically overt AL amyloidosis evaluated in the frame of routine clinical assessments) will be either referred to the Amyloidosis Research and Treatment Center in Pavia or managed locally, with clinical data prospectively entering a disease registry and diagnostic leftovers from biospecimens stored in a biorepository. This will aim to increase referral and increment inclusion of real-world cases of AL amyloidosis in the disease registry and linked biorepositories, as well as patients' enrollment in other already approved and funded pre-clinical and clinical studies on basic disease mechanisms, as well as new diagnostic/therapeutic approaches in AL amyloidosis.

Part C: exploiting data collected from patients enrolled in both part A and part B, the clinical utility of clonal light chain profiling (including light chain sequencing, evaluation of the N-glycosylation status, and artificial intelligence-based amyloidogenicity prediction) will be assessed.

03

Conditions studied

  • AL Amyloidosis
  • Smoldering Multiple Myeloma
  • Monoclonal Gammopathy of Undetermined Significance
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The participating Departments of Hematology will be involved in screening at-risk patients with monoclonal gammopathies and refer suspected/confirmed AL cases to the Amyloidosis Center in Pavia.

Eligibility criteria

PART A

Inclusion Criteria:

  • diagnosis of MGUS with altered FLCR or SMM;
  • treatment-naïve;
  • age ≥18 years;
  • ability to understand and willingness to sign an ;
  • planned follow-up at participating center.

Exclusion Criteria:

  • Diagnosis of symptomatic monoclonal gammopathies;
  • Previous treatment for monoclonal gammopathies.

PART B

Inclusion criteria:

  • diagnosis of systemic AL amyloidosis;
  • treatment-naïve;
  • age ≥18 years;
  • ability to understand and willingness to sign an informed consent;
  • planned follow-up at participating center.

Exclusion criteria:

  • non-AL amyloidosis;
  • previous treatment for AL amyloidosis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
760 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Patients with MGUS and aFLCR and with SMM

    Part A: Patients with MGUS and aFLCR and patients with SMM undergoing an active, biomarker-based screening of presymptomatic amyloid organ involvement. Part B: Newly diagnosed patients with AL amyloidosis identified through Part A or with clinically overt AL amyloidosis evaluated in the frame of routine clinical assessments and referred to the Amyloidosis Research and Treatment Center in Pavia or managed locally at the participating Italian Hematologic Departments

    Other: no intervention

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Assess proportion of patients with newly diagnosed AL identified through the biomarker-based screening of at-risk patient

    Part A of the study: the proportion of patients with newly diagnosed AL through the biomarker-based screening of at-risk patients with a known monoclonal gammopathy will be identified.

    Time frame: 2 years

  2. Assess the proportion of patients with deep haematological response after frontline therapy (best response evaluation) in the new enhanced, contemporary, real-world series of AL patients enrolled during the study.

    Part B of the study: The proportion of patients with deep hematological response after frontline therapy will be assessed

    Time frame: 2 years

  3. 3. Identify associations of clonal light chain features with different clinical features at baseline.

    Part C of the study: Associations of clonal light chain features with different clinical features at baseline, including organ tropism and clonal burden, will be assessed.

    Time frame: 2 years

Secondary outcomes

  1. Description of the baseline characteristics and 6-months outcome, as well as the time to AL development for patients with AL identified through the biomarker-based screening

    Part A: the baseline characteristics and 6-months outcome, as well as the time to AL development for patients with AL identified through the biomarker-based screening will be evaluated

    Time frame: 6 months

  2. Description of the baseline characteristics of MGUS/SMM patients with abnormal FLCR

    Part A: the baseline characteristics of MGUS/SMM patients with abnormal FLCR will be described

    Time frame: 2 years

  3. Identification of clinical and biological correlates of hematological response

    part B: clinical and biological correlates of hematological response will be identified

    Time frame: 2 years

  4. To verify whether implementing a dedicated pipeline for referral of AL patients to the National Referral Center will increase the proportion of patients from spoke centers

    Part B: it will be verified if implementing a dedicated pipeline for referral of AL patients to the National Referral Center will increase the proportion of patients from spoke centers

    Time frame: 2 years

  5. Identification of associations of clonal light chain features with event-free survival

    Part C: associations of clonal light chain features with event-free survival will be identified.

    Time frame: 2 years

  6. Validation of existing algorithms for predicting AL amyloidosis status

    Part C: The diagnostic performance of existing algorithms for predicting clonal light chain amyloidogenicity will be evaluated.

    Time frame: 2 years

07

Study locations

4 of 4 sites recruiting
  • Azienda Ospedaliera Policlinico Consorziale
    Bari, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria Policlinico G.Rodolico - San Marco
    Catania, Italy
    Recruiting
    • Francesco Di Raimondo, MD · Contactsegremat@unict.it · 095/378.1956
    • Francesco Di Raimondo, MD · Principal investigator
    • Concetta Maria Sebastiana Conticello, MD, PhD · Sub investigator
  • Fondazione Irccs Policlinico San Matteo
    Pavia, Italy
    Recruiting
    • GIOVANNI PALLADINI, MD, PhD · Contactsegreteria.amiloidosi@smatteo.pv.it · +390382502994
    • GIOVANNI PALLADINI, MD, PhD · Principal investigator
    • Luca Arcaini, MD · Principal investigator
    • Mario Ulisse Nuvolone, MD, PhD · Sub investigator
  • EMATOLOGIA - Città della Scienza e Salute - Torino
    Torino, Italy
    Recruiting
    • FRANCESCA MARIA GAY, MD, PhD · Contactematologia@cittadellasalute.to.it · 011.633.5550 - 5935
    • FRANCESCA MARIA GAY, MD, PhD · Principal investigator
    • Stefania Oliva, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for May 2026, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2024
First posted
Apr 25, 2024
StartActual
May 1, 2023
Primary completionEst.
May 1, 2026
CompletionEst.
May 1, 2026
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06383143
Responsible party
Giovanni Palladini (MD, PhD, Fondazione IRCCS Policlinico San Matteo di Pavia) — Principal investigator
First posted
Apr 25, 2024
Start date
May 1, 2023
Primary completion
May 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Apr 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion